Trial Profile
A Ph2, Randomized, Open-Label, Multicenter, Three-Arm Trial of Sym004 Versus Each of Its Component Futuximab and Modotuximab, in Patients With Chemotherapy-Refractory Metastatic Colorectal Carcinoma and Acquired Resistance to Anti-EGFR mAb
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Futuximab/modotuximab (Primary) ; Futuximab; Modotuximab
- Indications Carcinoma; Colorectal cancer
- Focus Adverse reactions
- Sponsors Symphogen
- 11 Apr 2019 Status changed from active, no longer recruiting to discontinued.
- 31 Jan 2019 This trial has been discontinued in Spain.
- 03 Dec 2018 Status changed from recruiting to active, no longer recruiting.